Key Highlights
- Profusa (NASDAQ:PFSA) signed a non-binding term sheet to acquire a privately held, commercial-stage diagnostics and toxicology testing company with estimated 2025 net revenues of approximately $111 million.
- The combined entity is expected to operate as a public diagnostics company with national CLIA-certified laboratories serving addiction treatment, pain management, and behavioral health providers.
- Jack Stover has been named Executive Chairman and Chief Executive Officer, while Ben Hwang has transitioned from CEO to President, and Liviu Goldenberg joins as an independent director.
- Profusa expects to close on approximately $7 million in subordinated convertible note financing concurrent with the transaction, alongside a share and preferred stock consideration structure.
A Non-Binding Term Sheet Sets the Stage for a Diagnostics Combination
Profusa has entered into a non-binding term sheet to acquire a privately held, commercial-stage health diagnostics and toxicology testing company, positioning the combined business to operate as a public diagnostics company with national CLIA-certified laboratories. The target company generates recurring revenue from a diversified base of providers across addiction treatment, pain management, and behavioral health, with estimated 2025 net revenues of approximately 111 million dollars based on unaudited management information.
The announcement pairs the proposed acquisition with a broader leadership transition at Profusa, signaling a coordinated shift in both strategic direction and executive structure as the company works toward a definitive agreement.
Leadership Overhaul Accompanies the Proposed Transaction
Profusa's board appointed Jack Stover, previously a director, as Executive Chairman and Chief Executive Officer, while Ben Hwang, who had served as Chief Executive Officer, Chairman, and Director, moved into the role of President. The board also added Liviu Goldenberg as an independent director, bringing more than three decades of experience in complex operations, technology adoption, and enterprise transformation, along with a background in capital raises and strategic partnerships.
On the financial structure, Profusa expects to issue Dx Company stockholders shares equal to 19.99% of its outstanding common stock upon execution of a definitive agreement, with the remainder delivered as non-voting convertible preferred stock subject to shareholder approval. Profusa's existing convertible notes and obligations are also expected to be exchanged for preferred stock, while the company anticipates closing approximately 7 million dollars in subordinated convertible note financing, carrying a 9% original issue discount and a 7% annual interest rate, rising to 18% in the event of default.
Deal Completion Hinges on Diligence, Documentation, and Shareholder Approval
The transaction remains non-binding and subject to due diligence, definitive documentation, and shareholder approval of the preferred stock conversion terms, meaning the timeline and final structure could still shift materially before closing. A successful combination could diversify Profusa's revenue base by adding an established, cash-generating diagnostics business to its existing biosensor technology platform, potentially strengthening its position as a public company with recurring laboratory revenue.
At the same time, the reliance on unaudited management estimates for the target's revenue figures, combined with the complexity of the proposed consideration structure involving both common and preferred stock, introduces execution risk that could affect deal terms or timing. The financing terms attached to the convertible notes, including the default interest rate, also point to a capital structure that will require careful management through closing.
Conclusion
Profusa's term sheet to acquire a commercial-stage diagnostics company marks a significant strategic pivot, pairing an established, revenue-generating toxicology testing business with the company's digital health biosensor platform. The accompanying leadership changes, including new executive roles for Jack Stover and Ben Hwang and the addition of an independent director, suggest a broader organizational reset alongside the deal. Whether the transaction proceeds to a definitive agreement may depend on the outcome of due diligence, the finalization of financing terms, and shareholder approval of the preferred stock conversion structure in the months ahead.



_11_17_2026_18_51_41_746812.jpg)


Please wait processing your request...